BioGenomics
Biogenomics Limited is an India-based biopharmaceutical company focused on diabetes and oncology. The company operates GLP‑compliant R&D facilities and WHO‑GMP biomanufacturing and fill/finish sites, develops recombinant proteins and analytical assays, pursues biosimilar biologics and novel formulations, and engages in partnerships for commercialisation.
Industries
Nr. of Employees
medium (51-250)
Patents
Products
GMP‑grade recombinant enzymes (animal‑origin‑free)
Recombinant trypsin, recombinant carboxypeptidase B, recombinant enterokinase and other enzymes produced under animal‑origin‑free conditions with defined activities and pack sizes for proteomics, cell culture and manufacturing use.
ELISA kits for process safety monitoring
Ready‑to‑use ELISA kits for detection of residual trypsin, residual carboxypeptidase B and host cell proteins (E. coli) to support purification process monitoring and product release testing.
Biopharmaceutical pipeline (development projects)
In‑development biosimilars and biologics, with a focus on insulin analogues, GLP‑1 analogs and monoclonal antibodies for oncology and metabolic diseases.
BIOGNIDE
BIOGNIDE-T is a combination of Metformin & Teneligliptin for better glycemic control. The Solphilic technology used in the formulation makes BIOGNIDE-T unique amongst another currently marketed brands, allowing it to disintegrate faster with a higher dissolution rate and improved bioavailability.
BIOGNIDE-GV1
A triple drug therapy containing Metformin Hydrochloride (SR), Glimepiride, and Voglibose for Type-2 diabetes care with an advanced formulation that enables faster disintegration.
BIOGNIDE-GV2
A higher strength triple drug therapy containing Metformin Hydrochloride (SR), Glimepiride, and Voglibose designed for advanced Type-2 diabetes care.
GMP‑grade recombinant enzymes (animal‑origin‑free)
Recombinant trypsin, recombinant carboxypeptidase B, recombinant enterokinase and other enzymes produced under animal‑origin‑free conditions with defined activities and pack sizes for proteomics, cell culture and manufacturing use.
ELISA kits for process safety monitoring
Ready‑to‑use ELISA kits for detection of residual trypsin, residual carboxypeptidase B and host cell proteins (E. coli) to support purification process monitoring and product release testing.
Biopharmaceutical pipeline (development projects)
In‑development biosimilars and biologics, with a focus on insulin analogues, GLP‑1 analogs and monoclonal antibodies for oncology and metabolic diseases.
BIOGNIDE
BIOGNIDE-T is a combination of Metformin & Teneligliptin for better glycemic control. The Solphilic technology used in the formulation makes BIOGNIDE-T unique amongst another currently marketed brands, allowing it to disintegrate faster with a higher dissolution rate and improved bioavailability.
BIOGNIDE-GV1
A triple drug therapy containing Metformin Hydrochloride (SR), Glimepiride, and Voglibose for Type-2 diabetes care with an advanced formulation that enables faster disintegration.
BIOGNIDE-GV2
A higher strength triple drug therapy containing Metformin Hydrochloride (SR), Glimepiride, and Voglibose designed for advanced Type-2 diabetes care.
Services
cGMP drug substance and drug product manufacturing including upstream fermentation, downstream purification, refolding, formulation and combi fill‑finish for vials, cartridges and pre‑filled syringes.
Manufacture of animal‑origin‑free recombinant enzymes and proteins expressed in E. coli across small to gram scale with GMP grade formats.
Analytical testing and immunoassay (ELISA) development for residual enzyme detection and host cell protein monitoring, plus structural and receptor‑binding studies.
Expression system development, codon optimisation, vector and protein engineering, and gene expression studies.
End‑to‑end bench‑to‑batch services for biotechnology projects (referenced service brand).
cGMP drug substance and drug product manufacturing including upstream fermentation, downstream purification, refolding, formulation and combi fill‑finish for vials, cartridges and pre‑filled syringes.
Manufacture of animal‑origin‑free recombinant enzymes and proteins expressed in E. coli across small to gram scale with GMP grade formats.
Analytical testing and immunoassay (ELISA) development for residual enzyme detection and host cell protein monitoring, plus structural and receptor‑binding studies.
Expression system development, codon optimisation, vector and protein engineering, and gene expression studies.
End‑to‑end bench‑to‑batch services for biotechnology projects (referenced service brand).
Expertise Areas
- Recombinant protein production
- Bioprocessing and scale‑up
- Analytical characterization and comparability
- Formulation development and fill/finish
Key Technologies
- Bacterial fermentation and bioreactors
- Protein purification and refolding
- Lyophilization (freeze drying)
- LC‑MS/MS (Q‑TOF)
News & Updates
Publication reporting physicochemical and structural comparisons to support biosimilarity of an insulin aspart candidate.
Press coverage and announcements about a partnership to launch a biosimilar insulin aspart product in India.
Peer‑reviewed comparative characterisation work published in a scientific journal demonstrating biosimilarity analyses for an insulin aspart candidate.
Multiple press reports documenting a partnership to commercialise a biosimilar insulin aspart in India.
Publication reporting physicochemical and structural comparisons to support biosimilarity of an insulin aspart candidate.
Press coverage and announcements about a partnership to launch a biosimilar insulin aspart product in India.
Peer‑reviewed comparative characterisation work published in a scientific journal demonstrating biosimilarity analyses for an insulin aspart candidate.
Multiple press reports documenting a partnership to commercialise a biosimilar insulin aspart in India.